CD15


Also found in: Acronyms, Wikipedia.

CD15

a phosphatidylinositol-anchored transmembrane protein found on neutrophils; it may be involved in phagocytosis; expressed in patients with Hodgkin disease, some B-cell chronic lymphocytic leukemias, acute lymphoblastic leukemias, and most acute nonlymphocytic leukemias.

CD15

This is a retired HUGO symbol for what molecular biologists now term FUT4 (see there). In practice, CD15 is widely used by haematologists, immunologists, laboratorians, pathologists and many others.
Mentioned in ?
References in periodicals archive ?
According to the WHO classification (2), Hodgkin and Reed-Sternberg cells are almost always positive for CD30 and positive for CD15 in 75-85% of cases.
Conclusion: We found that a panel including calretinin and CK5/6 for malignant mesothelioma and CEA and CD15 for adenocarcinoma and additionally EMA and TTF-1 avoided the difficulty in all cases.
Immunohistochemistry: Formalin-fixed paraffin- embedded LN specimens were stained immunohistochemically with primary monoclonal antibodies against CD45, CD20, CD45RO, CD15 and CD30 antigens for immunophenotyping and classifying HL according to the WHO classification (15), bcl-2 (clone 124), p53 (clone DO7), EBV-LMP1 (clone CS 1-4), Ki-67 (clone MIB-1) and with polyclonal rabbit anti bak, as described earlier (11).
Further workup with immunohistochemical stains revealed that the lesion was CD45 positive (hematopoietic); it also stained with CD15, CD68, and CD168 (Figure 2).
Seven monoclonal antibodies for a set of leukocyte surface antigens (including CD13, CD15, CD33, CD34, HLA-DR, CD14, and CD45) have been immobilized on a modified slide (left side of Fig.
These cells were focally positive for CD3O (Ki1) and Ebstein-Barr virus latent membrane protein-1 (EBVLMP-1) and negative for CD15 (Leu-M1).
This request is for a one-time purchase of two (2) Lily Corporation CD15 Epoxy Injection Dispenser for the Michigan Department of Transportation (MDOT).
Usual B and T cell markers (CD3, CD5, CD10, CD15, CD20, CD79a, PAX5) were negative, and activation markers (CD30 and MUM1) were positive in this tumor.
Accordingly, reactivity for the lymphoid markers Tdt, CD2, CD7, and CD19 was demonstrated in MPO+ myeloid leukemic cells (68-73, 75-80), whereas positivity for the myeloid antigens CD13, CD33, and CD15 can be found in a variable proportion of ALL cases (50, 54, 74).
Immunohistochemically, the tumor cells are positive for CD15, CD30, Pax5, and rarely CD20, and negative for T-cell markers.